SEARCH

SEARCH BY CITATION

References

  • 1
    Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in europe. Results of the european prevalence of infection in intensive care (epic) study. Epic international advisory committee. JAMA 1995; 274: 639644.
  • 2
    Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160: 608613.
  • 3
    American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388416.
  • 4
    Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American surveillance study (2000–2002). Ann Clin Microbiol Antimicrob 2004; 3: 14.
  • 5
    Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific rim, Europe and Latin and North America collected as part of test and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60: 10181029.
  • 6
    Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 2008; 6: 3949.
  • 7
    Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 13331341.
  • 8
    Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8: 751762.
  • 9
    Rios FG, Luna CM, Maskin B et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007; 30: 307313.
  • 10
    Kallel H, Bahloul M, Hergafi L et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28: 366369.
  • 11
    Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 1125.
  • 12
    Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4: 138146.
  • 13
    Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57: 306311.
  • 14
    Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754757.
  • 15
    Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162: 328330.
  • 16
    Goldstein FW, Ly A, Kitzis MD. Comparison of etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin. J Antimicrob Chemother 2007; 59: 10391040.
  • 17
    Rea-Neto A, Youssef NC, Tuche F et al. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care 2008; 12: R56.
  • 18
    Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102: 407412.
  • 19
    Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43 (Suppl 2): S8994.
  • 20
    Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007; 60: 12161226.
  • 21
    Lesho E. Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2005; 3: 445451.
  • 22
    Canton R, Cobos N, De Gracia J et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005; 11: 690703.
  • 23
    Sermet-Gaudelus I, Le Cocguic Y, Ferroni A et al. Nebulized antibiotics in cystic fibrosis. Paediatr Drugs 2002; 4: 455467.
  • 24
    Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 25882598.
  • 25
    Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117: 14341442.
  • 26
    Michalopoulos A, Falagas ME. Colistin and polymyxin b in critical care. Crit Care Clin 2008; 24: 377391, x.
  • 27
    Dhand R, Sohal H. Pulmonary drug delivery system for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008; 5: 918.
  • 28
    Georgopoulos D, Mouloudi E, Kondili E, Klimathianaki M. Bronchodilator delivery with metered-dose inhaler during mechanical ventilation. Crit Care 2000; 4: 227234.